

## **Clinical Policy: Baricitinib (Olumiant)**

Reference Number: CP.PHAR.135

Effective Date: 07.24.18

Last Review Date: 08.24

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Baricitinib (Olumiant<sup>®</sup>) is Janus kinase (JAK) inhibitor.

### **FDA Approved Indication(s)**

Olumiant is indicated for the treatment of:

- Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies
- Coronavirus disease 2019 (COVID-19) in hospitalized adult patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
- Adult patients with severe alopecia areata

Limitation(s) of use: Use of Olumiant in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs) or immunomodulators, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Olumiant is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Coronavirus-19 Infection:**

1. Initiation of outpatient treatment will not be authorized as Olumiant is FDA-approved for use only in the hospitalized setting.

**Approval duration: Not applicable**

##### **B. Rheumatoid Arthritis (must meet all):**

1. Diagnosis of RA per American College of Rheumatology (ACR) criteria (*see Appendix E*);
2. Prescribed by or in consultation with a rheumatologist;
3. Age  $\geq$  18 years;
4. Member meets one of the following (a or b):
  - a. Failure of a  $\geq$  3 consecutive month trial of methotrexate (MTX) at up to maximally indicated doses;

- b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq 3$  consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member has not responded or is intolerant to one or more TNF antagonists (e.g., *Hadlima*<sup>™</sup>, *Simlandi*<sup>®</sup>, *Yusimry*<sup>™</sup>, *adalimumab-aaty*, *adalimumab-adaz*, *adalimumab-adbm*, and *adalimumab-flkp* are preferred), unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for TNF antagonists*
6. Failure of  $\geq 3$  consecutive months of Actemra<sup>®</sup>, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for Actemra*
7. Documentation of one of the following baseline assessment scores (a or b):
  - a. Clinical disease activity index (CDAI) score (*see Appendix F*);
  - b. Routine assessment of patient index data 3 (RAPID3) score (*see Appendix G*);
8. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
9. Dose does not exceed both of the following (a and b):
  - a. 2 mg per day;
  - b. 1 tablet per day.

**Approval duration: 6 months**

**C. Alopecia Areata:**

1. Use of Olumiant for the treatment of alopecia areata is a benefit exclusion and will not be authorized because it is considered cosmetic in nature.

**Approval duration: Not applicable**

**D. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Coronavirus-19 Infection:

1. Continuation of therapy in the outpatient setting will not be authorized as Olumiant is FDA-approved for use only in the hospitalized setting for 14 days or until discharged from the hospital, whichever comes first.

**Approval duration: Not applicable**

### B. Rheumatoid Arthritis (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
  - a. A decrease in CDAI (*see Appendix F*) or RAPID3 (*see Appendix G*) score from baseline;
  - b. Medical justification stating inability to conduct CDAI re-assessment, and submission of RAPID3 score associated with disease severity that is similar to initial CDAI assessment or improved;
3. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
4. If request is for a dose increase, new dose does not exceed both of the following (a and b):
  - a. 2 mg per day;
  - b. 1 tablet per day.

**Approval duration: 12 months**

### C. Alopecia Areata:

1. Use of Olumiant for the treatment of alopecia areata is a benefit exclusion and will not be authorized because it is considered cosmetic in nature.

**Approval duration: Not applicable**

### D. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Combination use with biological disease-modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants, including but not limited to any tumor necrosis factor (TNF) antagonists [e.g., Cimzia<sup>®</sup>, Enbrel<sup>®</sup>, Humira<sup>®</sup> and its biosimilars, Remicade<sup>®</sup> and its biosimilars (Avsola<sup>™</sup>, Inflectra<sup>™</sup>, Renflexis<sup>™</sup>, Zymfentra<sup>®</sup>), Simponi<sup>®</sup>], interleukin agents [e.g., Actemra<sup>®</sup> (IL-6RA), Arcalyst<sup>®</sup> (IL-1 blocker), Bimzelx<sup>®</sup> (IL-17A and F antagonist), Cosentyx<sup>®</sup> (IL-17A inhibitor), Ilaris<sup>®</sup> (IL-1 blocker), Ilumya<sup>™</sup> (IL-23 inhibitor), Kevzara<sup>®</sup> (IL-6RA), Kineret<sup>®</sup> (IL-1RA), Omvoh<sup>™</sup> (IL-23 antagonist), Siliq<sup>™</sup> (IL-17RA), Skyrizi<sup>™</sup> (IL-23 inhibitor), Stelara<sup>®</sup> (IL-12/23 inhibitor), Taltz<sup>®</sup> (IL-17A inhibitor), Tofidence<sup>™</sup> (IL-6), Tremfya<sup>®</sup> (IL-23 inhibitor), Wezlana<sup>™</sup> (IL-12/23 inhibitor)], Janus kinase inhibitors (JAKi) [e.g., Cibinqo<sup>™</sup>, Olumiant<sup>™</sup>, Rinvoq<sup>™</sup>, Xeljanz<sup>®</sup>/Xeljanz<sup>®</sup> XR,], anti-CD20 monoclonal antibodies [Rituxan<sup>®</sup> and its biosimilars (Riabni<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup>), Rituxan Hycela<sup>®</sup>], selective co-stimulation modulators [Orencia<sup>®</sup>], integrin receptor antagonists [Entyvio<sup>®</sup>], tyrosine kinase 2 inhibitors [Sotyktu<sup>™</sup>], and sphingosine 1-phosphate receptor modulator [Velsipity<sup>™</sup>] because of the additive immunosuppression, increased risk of neutropenia, as well as increased risk of serious infections;
- C. Treatment of alopecia areata because it is considered cosmetic in nature.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CDAI: clinical disease activity index	JAK: Janus kinase
COVID-19: coronavirus disease 2019	MTX: methotrexate
DMARD: disease-modifying antirheumatic drug	RA: rheumatoid arthritis
ECMO: extracorporeal membrane oxygenation	RAPID3: routine assessment of patient index data 3
FDA: Food and Drug Administration	TNF: tumor necrosis factor

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
azathioprine (Azasan <sup>®</sup> , Imuran <sup>®</sup> )	RA 1 mg/kg/day PO QD or divided BID	2.5 mg/kg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Cuprimine <sup>®</sup> (d-penicillamine)	<b>RA*</b> <u>Initial dose:</u> 125 or 250 mg PO QD <u>Maintenance dose:</u> 500 to 750 mg/day PO QD	1,500 mg/day
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>RA</b> 2.5 to 4 mg/kg/day PO divided BID	4 mg/kg/day
hydroxychloroquine (Plaquenil <sup>®</sup> )	<b>RA*</b> <u>Initial dose:</u> 400 to 600 mg/day PO QD <u>Maintenance dose:</u> 200 to 400 mg/day PO QD	600 mg/day
leflunomide (Arava <sup>®</sup> )	<b>RA</b> <u>Initial dose (for low risk hepatotoxicity or myelosuppression):</u> 100 mg PO QD for 3 days <u>Maintenance dose:</u> 20 mg PO QD	20 mg/day
methotrexate (Trexall <sup>®</sup> , Otrexup <sup>™</sup> , Rasuvo <sup>®</sup> , RediTrex <sup>®</sup> , Xatmep <sup>™</sup> , Rheumatrex <sup>®</sup> )	<b>RA</b> 7.5 mg/week PO, SC, or IM or 2.5 mg PO Q12 hr for 3 doses/week	30 mg/week
Ridaura <sup>®</sup> (auranofin)	<b>RA</b> 6 mg PO QD or 3 mg PO BID	9 mg/day (3 mg TID)
sulfasalazine (Azulfidine <sup>®</sup> )	<b>RA</b> <u>Initial dose:</u> 500 mg to 1,000 mg PO QD for the first week. Increase the daily dose by 500 mg each week up to a maintenance dose of 2 g/day. <u>Maintenance dose:</u> 2 g/day PO in divided doses	3 g/day
Hadlima (adalimumab- bwwd), Simlandi (adalimumab-ryvk), Yusimry (adalimumab- aqvh), adalimumab-aaty (Yuflyma <sup>®</sup> ), adalimumab-adaz (Hyrimoz <sup>®</sup> ), adalimumab-fkjp	<b>RA</b> 40 mg SC every other week  Some patients with RA not receiving concomitant methotrexate may benefit from increasing the frequency to 40 mg every week or 80 mg every other week.	40 mg/week

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
(Hulio <sup>®</sup> ), adalimumab-adbm (Cyltezo <sup>®</sup> )		
Tocilizumab (Actemra)	<p><b>RA</b></p> <p>IV: 4 mg/kg every 4 weeks followed by an increase to 8 mg/kg every 4 weeks based on clinical response</p> <p>SC: Weight &lt; 100 kg: 162 mg SC every other week, followed by an increase to every week based on clinical response Weight ≥ 100 kg: 162 mg SC every week</p>	<p>IV: 800 mg every 4 weeks</p> <p>SC: 162 mg every week</p>

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

\*Off-label

#### Appendix C: Contraindication/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): serious infection, malignancy, thrombosis, higher rate of major adverse cardiovascular events (cardiovascular death, myocardial infarction and stroke), and higher rates of all-causes mortality

#### Appendix D: General Information

- Definition of failure of MTX or DMARDs:
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- TNF blockers:
  - Etanercept (Enbrel<sup>®</sup>), adalimumab (Humira<sup>®</sup>) and its biosimilars, infliximab (Remicade<sup>®</sup>) and its biosimilars (Avsola<sup>™</sup>, Renflexis<sup>™</sup>, Inflectra<sup>®</sup>), certolizumab pegol (Cimzia<sup>®</sup>), and golimumab (Simponi<sup>®</sup>, Simponi Aria<sup>®</sup>).

#### Appendix E: The 2010 ACR Classification Criteria for RA

Add score of categories A through D; a score of ≥ 6 out of 10 is needed for classification of a patient as having definite RA.

<b>A</b>	<b>Joint involvement</b>	<b>Score</b>
	1 large joint	0
	2-10 large joints	1
	1-3 small joints (with or without involvement of large joints)	2
	4-10 small joints (with or without involvement of large joints)	3
	> 10 joints (at least one small joint)	5
<b>B</b>	<b>Serology (at least one test result is needed for classification)</b>	
	Negative rheumatoid factor (RF) <i>and</i> negative anti-citrullinated protein antibody (ACPA)	0
	Low positive RF <i>or</i> low positive ACPA <i>* Low: &lt; 3 x upper limit of normal</i>	2
	High positive RF <i>or</i> high positive ACPA <i>* High: ≥ 3 x upper limit of normal</i>	3
<b>C</b>	<b>Acute phase reactants (at least one test result is needed for classification)</b>	
	Normal C-reactive protein (CRP) and normal erythrocyte sedimentation rate (ESR)	0
	Abnormal CRP or abnormal ESR	1
<b>D</b>	<b>Duration of symptoms</b>	
	< 6 weeks	0
	≥ 6 weeks	1

*Appendix F: Clinical Disease Activity Index (CDAI) Score*

The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity in RA. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0–10 cm) Scale for estimating disease activity. The CDAI score ranges from 0 to 76.

<b>CDAI Score</b>	<b>Disease state interpretation</b>
≤ 2.8	Remission
> 2.8 to ≤ 10	Low disease activity
> 10 to ≤ 22	Moderate disease activity
> 22	High disease activity

*Appendix G: Routine Assessment of Patient Index Data 3 (RAPID3) Score*

The Routine Assessment of Patient Index Data 3 (RAPID3) is a pooled index of the three patient-reported ACR core data set measures: function, pain, and patient global estimate of status. Each of the individual measures is scored 0 – 10, and the maximum achievable score is 30.

<b>RAPID3 Score</b>	<b>Disease state interpretation</b>
≤ 3	Remission
3.1 to 6	Low disease activity
6.1 to 12	Moderate disease activity
> 12	High disease activity

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
RA	2 mg PO QD	2 mg/day

**VI. Product Availability**

Tablets: 1 mg, 2 mg, 4mg

**VII. References**

1. Olumiant Prescribing Information. Indianapolis, IN: Eli Lilly and Company; June 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/207924s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207924s004lbl.pdf). Accessed February 8, 2024.
2. Fraenkel L, Bathon JM, Enggland BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021; 73(7):924-939. DOI 10.1002/acr.24596.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2024. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed February 8, 2024.
4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed February 8, 2024.
5. Smolen JS, Landewe RB, Dergstra SA, et al. 2022 update of the EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Arthritis Rheumatology. 2023 January; 32:3-18. DOI:10.1136/ard-2022-223356.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2020 annual review: for RA, added specific diagnostic criteria for definite RA, baseline CDAI score requirement, and decrease in CDAI score as positive response to therapy; references reviewed and updated.	04.23.20	05.20
Revised typo in Appendix E from “normal ESR” to “abnormal ESR” for a point gained for ACR Classification Criteria.	11.22.20	
Added criteria for Coronavirus-19 Infection (FDA Emergency Use Authorization); Added criteria for RAPID3 assessment for RA given limited in-person visits during COVID-19 pandemic, updated appendices.	11.24.20	02.21
2Q 2021 annual review: added combination of bDMARDs under Section III; updated CDAI table with “>” to prevent overlap in classification of severity, updated dosage form to include 1 mg; references reviewed and updated.	02.23.21	05.21
RT4: EUA no longer requires baricitinib be used in combination with remdesivir.	08.04.21	
Per August SDC and prior clinical guidance, for RA added Actemra to redirect options and modified to require a trial of all; for Xeljanz redirection requirements added bypass for members with	08.25.21	11.21



Reviews, Revisions, and Approvals	Date	P&T Approval Date
cardiovascular risk and qualified redirection to apply only for member that has not responded or is intolerant to one or more TNF blockers.		
2Q 2022 annual review: for RA, removed redirections to Actemra, Kavzara, and Xeljanz per February SDC and applied FDA labeling update as second line after TNF antagonists; reiterated requirement against combination use with a bDMARD or JAKi from Section III to Sections I and II; references reviewed and updated.	02.20.22	05.22
RT4: revised FDA approved indications to include treatment of alopecia and hospitalized COVID-19; removed EUA criteria for COVID-19 (Appendix H); reiterated that Olumiant is not covered for COVID-19 since it is FDA-approved for use only in the hospital setting; added alopecia areata to the list of indications for which coverage is NOT authorized, since its use is cosmetic in nature and thus a benefit exclusion; references reviewed and updated.	06.28.22	
Template changes applied to other diagnoses/indications and continued therapy section.	09.30.22	
2Q 2023 annual review: no significant changes; updated off-label dosing in Appendix B; references reviewed and updated.	02.10.23	05.23
Per July SDC: for RA, updated criteria with examples of preferred TNF blockers: Humira biosimilars Yusimry, Hadlima, unbranded adalimumab-fkjp, and unbranded adalimumab-adaz; updated Appendix D with list of TNF blockers.	07.25.23	
Per December SDC, added adalimumab-adbm to listed examples of preferred TNF blockers; for RA added redirection to Actemra.	12.06.23	02.24
2Q 2024 annual review: added Bimzelx, Zymfentra, Omvoh, Wezlana, Sotyktu, Tofidence, and Velsipity to section III.B; references reviewed and updated.	01.23.24	05.24
Per June SDC: for RA, added Simlandi to listed examples of preferred adalimumab products. Per SDC: for RA, added unbranded adalimumab-aaty to listed examples of preferred adalimumab products.	07.23.24	08.24

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.